Skip to main content

Table 4 Pneumonia adverse events by post-bronchodilator FEV1 % predicted at baseline*

From: Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

 

Placebo

(n = 1544)

SAL

(n = 1542)

FP

(n = 1552)

SFC

(n = 1546)

FEV 1 < 30% predicted

    

   number of patients

215

261

223

246

   total treatment exposure (yrs)

378

511

487

546

   number of events

28

44

55

89

   rate‡

74

86

113

163

FEV 1 30% to < 50% predicted

    

   number of patients

786

750

785

735

   total treatment exposure (yrs)

1626

1686

1787

1752

   number of events

87

90

171

156

   rate‡

54

53

96

89

FEV 1 ≥ 50% predicted

    

   number of patients

543

531

544

565

   total treatment exposure (yrs)

1275

1334

1281

1402

   number of events

55

48

74

79

   rate‡

43

36

58

56

  1. *Safety population (n = 6184)
  2. ‡Rate per thousand treatment years, calculated as (events × 1000/total treatment exposure)